CASI Pharmaceuticals, Inc. is a biopharmaceutical firm focused on the development and market introduction of medical treatments and drugs across China, the United States, and globally. Its marketed product, EVOMELA, is an intravenous formulation of melphalan, utilized for conditioning prior to stem cell transplantation and as a palliative option for patients suffering from multiple myeloma. The company's developmental pipeline encompasses several experimental therapies.
| Date | Est. | Actual | |
|---|---|---|---|
| Nov 14, 2025 | -$0.40 | -$0.67 | Miss |
| Aug 29, 2025 | -$0.47 | -$0.86 | Miss |
| May 16, 2025 | -$0.61 | -$0.69 | Miss |
| Mar 31, 2025 | -$0.60 | -$0.79 | Miss |
| Nov 15, 2024 | -$0.62 | -$0.55 | Beat |
| Aug 16, 2024 | -$0.63 | -$0.52 | Beat |